Current Hematologic Malignancy Reports

, Volume 11, Issue 6, pp 456–461 | Cite as

Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM

  • Naveen Pemmaraju
  • Audun Utengen
  • Vikas Gupta
  • Jean-Jacques Kiladjian
  • Ruben Mesa
  • Michael A. Thompson
Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Social Media Impact of Hematologic Malignancies


The social media platform Twitter has provided the hematology/oncology community with unprecedented, novel methods of interpersonal communication and increased ability for the dissemination of important updates in a rapidly moving field. The advent, and subsequent success, of disease-specific Twitter communities have further enabled interested healthcare stakeholders to become quickly organized around a unique set of rare medical conditions, such as hematologic malignancies, that, historically, generally lack large amounts of reliable online information. One example is the Twitter community #MPNSM (myeloproliferative neoplasms on social media), which was started approximately one and half years ago and has served as a recognized venue for discussion among many members of the MPN community, including patients, researchers, providers, and advocacy organizations. This article will focus on understanding the impact of the founding of this community via the analysis of advanced Twitter metrics of user experience, from the first year of use for this novel healthcare hashtag.


Social media Twitter Myeloproliferative neoplasm Disease-specific hashtag Myelofibrosis Polycythemia vera 



This research is supported in part by the MD Anderson Cancer Center Support Grant P30 CA016672. The authors thank Dr Matthew Katz and the creators of the Cancer Ontology Tag (CTO) Program for their example and inspiration, and the founders and members of Symplur, and the Healthcare Hashtags Project for their continued analysis and support.

Compliance With Ethical Standards

Conflict of Interest

Naveen Pemmaraju reports Honorarium/Consulting and/or Research and Clinical trial support: Novartis, LFB, Incyte, Stemline, Cellectis.

Vikas Gupta received research grants from Novartis, Incyte, Gilead, and Promedior through his institution; served on scientific advisory board of Novartis, Incyte and received honorarium from Novartis/Incyte.

Audun Utengen is the Co-founder of Symplur.

Michael A. Thompson has been on Advisory Boards for: AIM Specialty Health, BMS, Celgene, Doximity, MDRing, Takeda, VIA Oncology, and Xconomy. Dr. Thompson owns stock in Doximity.

Ruben Mesa is the Editor-in-Chief of Current Hematologic Malignancy Reports.

Jean-Jacques Kiladjian reports grants from Novartis and AOP Orphan and personal fees from Novartis, Incyte, AOP Orphan, and Shire.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. 1.
    Abernethy AP, Grubbs SS. Managing cumulative expectations in oncology: challenges and potential solutions. Am Soc Clin Oncol Educ Book. 2014;e140-144. doi: 10.14694/EdBook_AM.2014.34.e140
  2. 2.
    Savage N. Scientists in the twitterverse. Cell. 2015;162(2):233–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Thompson MA. Using social media to learn and communicate: it is not about the tweet. Am Soc Clin Oncol Educ Book. 2015;206–211.Google Scholar
  4. 4.
    Borgmann H, Loeb S, Salem J, et al. Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. Urol Oncol. 2016.Google Scholar
  5. 5.
    Attai DJ, Cowher MS, Al-Hamadani M, Schoger JM, Staley AC, Landercasper J. Twitter social media is an effective tool for breast cancer patient education and support: patient-reported outcomes by survey. J sMed Internet Res. 2015;17(7):e188.CrossRefGoogle Scholar
  6. 6.
    Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social media and the practicing hematologist: twitter 101 for the busy healthcare provider. Curr Hematol Malig Rep. 2015;10(4):405–12.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Salem J, Borgmann H, Murphy DG. Integrating social media into urologic health care: what can we learn from other disciplines? Curr Urol Rep. 2016;17(2):13.CrossRefPubMedGoogle Scholar
  8. 8.
    Park S, Oh HK, Park G, et al. The source and credibility of colorectal cancer information on twitter. Medicine. 2016;95(7):e2775.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pemmaraju N, Moliterno AR. From Philadelphia-negative to JAK2-positive: effect of genetic discovery on risk stratification and management. Am Soc Clin Oncol Educ Book. 2015;35:139–45.CrossRefGoogle Scholar
  10. 10.
    Verstovsek S, Komrokji RS. Novel and emerging therapies for the treatment of polycythemia vera. Expert Rev Hematol. 2015;8(1):101–13.CrossRefPubMedGoogle Scholar
  11. 11.
    Geyer HL, Mesa RA. Emerging drugs for the treatment of myelofibrosis. Expert Opin Emerg Drugs. 2015;20(4):663–78.CrossRefPubMedGoogle Scholar
  12. 12.
    Stein BL, Gotlib J, Arcasoy M, et al. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015;13(4):424–34.PubMedGoogle Scholar
  13. 13.
    Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (mpn)-focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015.Google Scholar
  15. 15.
    Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33:6520.Google Scholar
  16. 16.
    Sedrak MS, Cohen RB, Merchant RM, Schapira MM. Cancer Communication in the Social Media Age. JAMA Oncol. 2016;2(6):822-3.Google Scholar
  17. 17.
    Perales MA, Drake EK, Pemmaraju N, Wood WA. Social media and the adolescent and young adult (aya) patient with cancer. Curr Hematol Malig Rep. 2016.Google Scholar
  18. 18.
    Thompson MA. Social media in clinical trials. Am Soc Clin Oncol Educ Book. 2014; e101-105. doi: 10.14694/EdBook_AM.2014.34.e101

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Naveen Pemmaraju
    • 1
  • Audun Utengen
    • 2
  • Vikas Gupta
    • 3
  • Jean-Jacques Kiladjian
    • 4
  • Ruben Mesa
    • 5
  • Michael A. Thompson
    • 6
  1. 1.Department of LeukemiaThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Symplur LLCLos AngelesUSA
  3. 3.The Elizabeth and Tony Comper MPN Program,-Princess Margaret Cancer CenterTorontoCanada
  4. 4.CIC (Clinical Investigations Center, INSERM CIC 1427) Hôpital Saint-Louis & Université Paris DiderotParisFrance
  5. 5.Division of Hematology & Medical Oncology, Mayo Clinic in ArizonaScottsdaleUSA
  6. 6.Aurora Research Institute, Aurora Health CareMilwaukeeUSA

Personalised recommendations